Dutour, A <br/><br/>
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.  [electronic resource] 

 -  Diabetes, obesity & metabolism  09 2016 
 - 882-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12680  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adipose Tissue--diagnostic imaging<br/>Diabetes Mellitus, Type 2--complications<br/>Exenatide<br/>Fatty Liver--complications<br/>Female<br/>Glycated Hemoglobin--metabolism<br/>Heart--diagnostic imaging<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Liver--diagnostic imaging<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Myocardium--metabolism<br/>Obesity--complications<br/>Pancreas--diagnostic imaging<br/>Peptides--therapeutic use<br/>Pericardium--diagnostic imaging<br/>Postprandial Period<br/>Proton Magnetic Resonance Spectroscopy<br/>Treatment Outcome<br/>Triglycerides--metabolism<br/>Venoms--therapeutic use